Concise commentary highlighting key findings, and providing valuable market intelligence
Definitions of key terms and concepts
Understand the universe of biosimilar and biobetter development
Get the complete picture of all products in the biosimilar pipeline
Know the latest status on specific biosimilar andbiobetter products of interest to you
Read about the most significant developments in every therapeutic area
Discover the levels of potential biosimilar and biobetter competition by therapy area and drug class
Analyze the size of the threat to your company's biologic portfolio
Learn which companies are potential future competitors
Key Questions Answered
When is the earliest potential launch for "Biosimilar X"?
What biosimilars are being developed in each therapeutic area, drug class, and compound class?
Which reference products are most targeted by biosimilar and biobetter developers?
Is the reference product sales value the key factor shaping biosimilar development priorities?
Which therapy areas are going to experience the most and fewest biosimilar entries?
Which companies are most active in the biosimilar and biobetter arena?
Which biosimilar companies have been most successful in getting their products onto the market?
How many new biosimilars will be on the market by 2014?
Who Would Benefit From This Report?
Strategic executives at originator, generic, and biosimilar/biobetter development companies, especially in:
Sales and Marketing
IP and Patent Affairs
Research & Development
Copyright©2012 PR Newswire.
All rights reserved